Vivimed Labs Q3FY26 Unaudited Results: Net Loss Widens to ₹165.66 Crore
Vivimed Labs reported unaudited standalone results for Q3FY26 with revenue at ₹116.31 crore and a net loss of ₹165.66 crore. Consolidated revenue was ₹159.89 crore with a net loss of ₹97.50 crore. Auditors issued a qualified report citing unprovided interest, commission provisions, and ongoing forensic audit evaluations.
The substantial losses and the qualified audit opinion, indicating potential material misstatements and unaddressed liabilities, will likely have a significant negative impact on investor confidence and the company's financial standing.
The company reported significant losses for the quarter on both standalone and consolidated bases, coupled with a qualified audit report highlighting several financial irregularities and unaddressed provisions.
Vivimed Labs Limited announced the outcome of its Board Meeting held on March 13, 2026, where the unaudited financial results (Standalone & Consolidated) for the quarter and nine months ending December 31, 2025, were approved.
For the third quarter ended December 31, 2025, the company reported a total revenue from operations of ₹116.31 crore on a standalone basis, with a total loss before tax of ₹165.66 crore. The diluted loss per share stood at ₹1.99.
On a consolidated basis for the same quarter, revenue from operations was ₹159.89 crore, and the loss before tax was ₹97.50 crore. The diluted earnings per share were reported as ₹0.89.
The auditors' limited review report highlighted several qualifications. These include the non-provision of interest, penal interest, and penal charges on loans amounting to ₹164.52 million (₹472.37 million year-to-date) on a consolidated basis. Additionally, the company has recognized a provision for commission expenses of ₹46.03 million related to earlier financial years, for which supporting documents are still being obtained. An extract from a forensic audit report for FY 2022-23 is also under evaluation for its potential financial impact.
What to do with a filing like this
Vivimed Labs Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Vivimed Labs Limited. Read the original for the full detail.